Patent US3789202A successfully refreshed from Google Patents.
Patent US5420136A successfully refreshed from Google Patents.
US5420136A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Eradication of pathogenic biological contaminants using non-azo naphthalimide dyes
Assignee: Alumend LLC
•
Filing: 1993-08-09
•
Granted: 1995-05-30
•
Expires: 2013-08-09
Abstract
Abstract A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
Inventors
- 👤 David E. Lewis
- 👤 Ronald E. Utecht
- 👤 Millard M. Judy
- 👤 J. Lester Matthews
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 16:45
CPC Classifications
C; C07; C07D; C07D221/00; C07D221/02; C07D221/04; C07D221/06; C07D221/14; A; A61; A61L; A61L2/00; A61L2/02; A61L2/16; C09; C09B; C09B57/00; C09B57/08; A61L2103/00; A61L2103/05; A61L2103/09
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
128 words
A method for eradicating a pathogenic biological contaminant from a target body tissue, said method comprising: admixing said target body tissue with an effective amount of: a non-azo N-substituted-1,8-naphthalimide compound substituted by, at a 3-position, a nucleofuge and, at a 4-position, a heteroatomic electron-releasing group, said heteroatomic electron-releasing group being characterized as having a heteroatom directly linked to said 4-position and having at least one hydrogen directly attached to said heteroatom, said non-azo N-substituted-1,8-naphthalimide compound being characterized as predominantly hydrophobic and, after being activated by a sufficient amount of activating agent gives an activated derivative, or a pharmaceutically acceptable salt thereof, to give a resultant body tissue; activating said resultant body tissue with a sufficient amount of an activating agent so as to eradicate said pathogenic biological contaminant.
Claim 2
Independent Claim
128 words
A method for eradicating a pathogenic biological contaminant from a target body tissue, said method comprising: admixing said target body tissue with an effective amount of: a non-azo N-substituted-1,8-naphthalimide compound substituted by, at a 3-position, a nucleofuge and, at a 4-position, a heteroatomic electron-releasing group, said heteroatomic electron-releasing group being characterized as having a heteroatom directly linked to said 4-position and having at least one hydrogen directly attached to said heteroatom, said non-azo N-substituted-1,8-naphthalimide compound being characterized as predominantly hydrophobic and, after being activated by a sufficient amount of activating agent gives an activated derivative, or a pharmaceutically acceptable salt thereof, to give a resultant body tissue; activating said resultant body tissue with a sufficient amount of an activating agent so as to eradicate said pathogenic biological contaminant.
Claim 3
Dependent Claim
30 words
The method of claim 1 wherein said body tissue is body fluid, packed red blood cell, packed white blood cell, cryo precipitate from blood plasma, plasma protein, skin or cornea.
Claim 4
Dependent Claim
23 words
The method of claim 2 wherein said body fluid is whole blood, blood plasma, serum, fluid from plasmapheresis, bone marrow or plasma fibrinogen.
Claim 5
Dependent Claim
15 words
The method of claim 2 wherein said body fluid is albumin, gamma globulin or semen.
Claim 6
Dependent Claim
11 words
The method of claim 1 wherein said body tissue is platelet.
Claim 7
Dependent Claim
17 words
The method of claim 1 wherein said pathogenic biological contaminant is virus, tumor cell, bacterium or parasite.
Claim 8
Independent Claim
135 words
A method for eradicating a pathogenic biological contaminant from a target body tissue, said method comprising: admixing said target body tissue with an effective amount of: a non-azo N-substituted-1,8-naphthalimide compound having at least two 1,8-naphthalimide moieties each substituted by, at a 3-position, a nucleofuge and, at a 4-position, a heteroatomic electron-releasing group, said heteroatomic electron-releasing group being characterized as having a heteroatom directly linked to said 4-position and having at least one hydrogen directly attached to said heteroatom, said non-azo N-substituted-1,8-naphthalimide compound being characterized as predominantly hydrophobic and after being activated by a sufficient amount of activating agent, gives an activated derivative, or a pharmaceutically acceptable salt thereof, to give a resultant body tissue; activating said resultant body tissue with a sufficient amount of an activating agent so as to eradicate said pathogenic biological contaminant.
Claim 9
Independent Claim
135 words
A method for eradicating a pathogenic biological contaminant from a target body tissue, said method comprising: admixing said target body tissue with an effective amount of: a non-azo N-substituted-1,8-naphthalimide compound having at least two 1,8-naphthalimide moieties each substituted by, at a 3-position, a nucleofuge and, at a 4-position, a heteroatomic electron-releasing group, said heteroatomic electron-releasing group being characterized as having a heteroatom directly linked to said 4-position and having at least one hydrogen directly attached to said heteroatom, said non-azo N-substituted-1,8-naphthalimide compound being characterized as predominantly hydrophobic and after being activated by a sufficient amount of activating agent, gives an activated derivative, or a pharmaceutically acceptable salt thereof, to give a resultant body tissue; activating said resultant body tissue with a sufficient amount of an activating agent so as to eradicate said pathogenic biological contaminant.
Claim 10
Dependent Claim
30 words
The method of claim 7 wherein said body tissue is body fluid, packed red blood cell, packed white blood cell, cryo precipitate from blood plasma, plasma protein, skin or cornea.
Claim 11
Dependent Claim
23 words
The method of claim 8 wherein said body fluid is whole blood, blood plasma, serum, fluid from plasmapheresis, bone marrow or plasma fibrinogen.
Claim 12
Dependent Claim
15 words
The method of claim 8 wherein said body fluid is albumin, gamma globulin or semen.
Claim 13
Dependent Claim
11 words
The method of claim 7 wherein said body tissue is platelet.
Claim 14
Dependent Claim
17 words
The method of claim 7 wherein said pathogenic biological contaminant is virus, tumor cell, bacterium or parasite.
Claim 15
Independent Claim
132 words
A method for eradicating a pathogenic biological contaminant from a target body tissue, said method comprising: activating, with a sufficient amount of an activating agent, a non-azo N-substituted-1,8-naphthalimide compound substituted by, at a 3-position, a nucleofuge and, at a 4-position, a heteroatomic electron-releasing group, said heteroatomic electron-releasing group being characterized as having a heteroatom directly linked to said 4-position and having at least one hydrogen directly attached to said heteroatom, said non-azo N-substituted-1,8-naphthalimide compound being characterized as predominantly hydrophobic and, after being activated by a sufficient amount of activating agent gives an activated derivative, or a pharmaceutically acceptable salt thereof, to give a resultant activated compound; and admixing a sufficient amount of said resultant activated compound with said target body tissue to eradicate said pathogenic biological contaminant in said target body tissue.
Claim 16
Independent Claim
132 words
A method for eradicating a pathogenic biological contaminant from a target body tissue, said method comprising: activating, with a sufficient amount of an activating agent, a non-azo N-substituted-1,8-naphthalimide compound substituted by, at a 3-position, a nucleofuge and, at a 4-position, a heteroatomic electron-releasing group, said heteroatomic electron-releasing group being characterized as having a heteroatom directly linked to said 4-position and having at least one hydrogen directly attached to said heteroatom, said non-azo N-substituted-1,8-naphthalimide compound being characterized as predominantly hydrophobic and, after being activated by a sufficient amount of activating agent gives an activated derivative, or a pharmaceutically acceptable salt thereof, to give a resultant activated compound; and admixing a sufficient amount of said resultant activated compound with said target body tissue to eradicate said pathogenic biological contaminant in said target body tissue.
Claim 17
Dependent Claim
30 words
The method of claim 13 wherein said body tissue is body fluid, packed red blood cell, packed white blood cell, cryo precipitate from blood plasma, plasma protein, skin or cornea.
Claim 18
Dependent Claim
23 words
The method of claim 14 wherein said body fluid is whole blood, blood plasma, serum, fluid from plasmapheresis, bone marrow or plasma fibrinogen.
Claim 19
Dependent Claim
15 words
The method of claim 14 wherein said body fluid is albumin, gamma globulin or semen.
Claim 20
Dependent Claim
11 words
The method of claim 13 wherein said body tissue is platelet.
Claim 21
Dependent Claim
17 words
The method of claim 13 wherein said pathogenic biological contaminant is virus, tumor cell, bacterium or parasite.
Claim 22
Independent Claim
139 words
A method for eradicating a pathogenic biological contaminant from a target body tissue, said method comprising: activating, with a sufficient amount of an activating agent, a non-azo N-substituted-1,8-naphthalimide compound having at least two 1,8-naphthalimide moieties each substituted by, at a 3-position, a nucleofuge and, at a 4-position, a heteroatomic electron-releasing group, said heteroatomic electron-releasing group being characterized as having a heteroatom directly linked to said 4-position and having at least one hydrogen directly attached to said heteroatom, said non-azo N-substituted-1,8-naphthalimide compound being characterized as predominantly hydrophobic and, after being activated by a sufficient amount of activating agent, gives an activated derivative, or a pharmaceutically acceptable salt thereof, to give a resultant activated compound; and admixing a sufficient amount of said resultant activated compound with said target body tissue to eradicate said pathogenic biological contaminant in said target body tissue.
Claim 23
Independent Claim
139 words
A method for eradicating a pathogenic biological contaminant from a target body tissue, said method comprising: activating, with a sufficient amount of an activating agent, a non-azo N-substituted-1,8-naphthalimide compound having at least two 1,8-naphthalimide moieties each substituted by, at a 3-position, a nucleofuge and, at a 4-position, a heteroatomic electron-releasing group, said heteroatomic electron-releasing group being characterized as having a heteroatom directly linked to said 4-position and having at least one hydrogen directly attached to said heteroatom, said non-azo N-substituted-1,8-naphthalimide compound being characterized as predominantly hydrophobic and, after being activated by a sufficient amount of activating agent, gives an activated derivative, or a pharmaceutically acceptable salt thereof, to give a resultant activated compound; and admixing a sufficient amount of said resultant activated compound with said target body tissue to eradicate said pathogenic biological contaminant in said target body tissue.
Claim 24
Dependent Claim
30 words
The method of claim 19 wherein said body tissue is body fluid, packed red blood cell, packed white blood cell, cryo precipitate from blood plasma, plasma protein, skin or cornea.
Claim 25
Dependent Claim
23 words
The method of claim 20 wherein said body fluid is whole blood, blood plasma, serum, fluid from plasmapheresis, bone marrow, or plasma fibrinogen.
Claim 26
Dependent Claim
15 words
The method of claim 20 wherein said body fluid is albumin, gamma globulin or semen.
Claim 27
Dependent Claim
11 words
The method of claim 19 wherein said body tissue is platelet.
Claim 28
Dependent Claim
17 words
The method of claim 19 wherein said pathogenic biological contaminant is virus, tumor cell, bacterium or parasite.
References Cited (Backward Citations)
US3959286A
Cited
US4006238A
Cited
US4062953A
Cited
US5183821A
Cited
US4594346A
Cited
US5177083A
Cited
DE3635711A1
Cited
US4874863A
Cited
US4878891A
Cited
US5091385A
Cited
US5086059A
Cited
US5206250A
Cited
US5206249A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-05-29 | 1998-11-28 | 1999-05-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-05-29 | 2002-11-28 | 2003-05-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-05-29 | 2006-11-28 | 2007-05-30 | $7700.00 | Window Closed / Lapsed |